The cooperation between both institutions, a press release indicates, will have a positive impact on the health of both countries.
According to the Pasteur Institute, the first and second stages of the Soberana 02 clinical trial were successfully concluded in Cuba and the third is about to be completed in Iran.
Scientists at the Cuban Institute announced that two doses of this vaccine shield the body with 62 percent immunity against SARS-CoV-2, origin of the Covid-19 pandemic, and if an injection of its counterpart Soberana Plus is added, it reaches 91.2 percent.
mh/msm/arc
